Wasserman T H
Mallinckrodt Institute of Radiology, Washington University Medical Center, St. Louis, MO 63110.
Semin Oncol. 1994 Oct;21(5 Suppl 11):21-5.
Radiotherapeutic studies with amifostine (WR-2721; Ethyol, US Bioscience, Inc, West Conshohocken, PA) are reviewed, with evidence that it offers clinical normal tissue protection and no evidence of any tumor protection. Conducting clinical trials with amifostine has been difficult because of the unique (toxicity) endpoints and concerns about tumor protection. The Radiation Therapy Oncology Group has conducted phase I studies and a phase II hemibody study, and is now in the process of conducting phase III amifostine studies. Amifostine remains the most promising compound for testing clinical radioprotection, and as new techniques are developed in radiation therapy to deliver higher doses of radiation, the protection of normal tissues will become even more important. This review will cover both the preclinical and clinical studies involving the use of amifostine with radiation therapy.
本文回顾了使用氨磷汀（WR-2721；Ethyol，美国生物科学公司，宾夕法尼亚州韦斯特康舍霍肯）的放射治疗研究，有证据表明它能对临床正常组织起到保护作用，且没有任何对肿瘤起保护作用的证据。由于其独特的（毒性）终点以及对肿瘤保护作用的担忧，开展氨磷汀的临床试验一直颇具难度。放射治疗肿瘤学组已进行了I期研究和一项II期半身照射研究，目前正在开展III期氨磷汀研究。氨磷汀仍是测试临床放射防护最具前景的化合物，随着放射治疗中新技术的发展以提供更高剂量的辐射，对正常组织的保护将变得更加重要。这篇综述将涵盖涉及氨磷汀与放射治疗联合使用的临床前和临床研究。
